Ocugen Inc. Announces Strategic Leadership Appointments to Enhance Gene Therapy Advancements

Reuters
21 Jul
<a href="https://laohu8.com/S/OCGN">Ocugen</a> Inc. Announces Strategic Leadership Appointments to Enhance Gene Therapy Advancements

Ocugen Inc. has announced updates to its Retina Scientific Advisory Board and Executive Leadership Team. Vijay Tammara, PhD, has been appointed as the Chief Development Officer, bringing extensive experience in global regulatory leadership. The company also introduced three renowned retinal surgeons to its advisory board to enhance guidance as it develops gene therapies for retinal diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9497664-en) on July 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10